Ocugen completes dosing of GARDian3 trial for OCU410ST ahead of schedule
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.
Search
Search results
Ocugen announce Phase 3 enrolment completion for OCU400, the largest gene agnostic therapy trial for RP
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
One-Year Survival of Transplanted Cells Marks Progress in Early Retinal Regeneration Studies
Researchers have recently presented promising clinical data at the International Society for Stem Cell Research demonstrating that transplanted human neural progenitor cells survived for at least one year in participants with Retinitis Pigmentosa (RP).
Seeing the light: Scientists use photoswitch drugs to restore vision in animal study
A consortium of researchers based at the Institute for Bioengineering of Catalonia (IBEC) have demonstrated that specially designed light-activated drugs can restore useful visual function in blind animals by making surviving retinal nerve cells respond to light.
Resources
From our newsletters to the recordings of our webinars and everything in-between, use the filters (below) to find the content that's right for you.
Information and support
Are you affected by inherited sight loss? We are here to help.
Approaches to treatment
The development of a new treatment is a lengthy process, from early investigation of ideas and principles in the lab, through testing in cell and animal models to the final stages of clinical trials in human patients. The good news is that progress is increasingly rapid.
Frequently asked questions
These frequently asked questions should provide a response for most of the queries you might raise.
Fundraising FAQs
Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.